Pamela McMillan

Pamela McMillan

Auto-generated profile, based on publicly available information

Pamela McMillan

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JWJeanna M. Wheeler
Jeanna M. Wheeler
PMPamela McMillan
Pamela McMillan
TSTimothy J. Strovas
Timothy J. Strovas
NLNicole F. Liachko
Nicole F. Liachko
AAAlexandre Amlie-Wolf
Alexandre Amlie-Wolf
BKBrian Kraemer
Brian Kraemer
Brain lesions composed of pathological tau help to drive neurodegeneration in Alzheimer’s disease (AD) and related tauopathies. Here, we identified the mammalian suppressor of tauopathy 2 (MSUT2) gene as a modifier of susceptibility to tau toxicity in two mouse models of tauopathy. Transgenic PS19 mice overexpressing tau, a model of AD, and lacking the Msut2 gene exhibited decreased learning and memory deficits, reduced neurodegeneration, and reduced accumulation of pathological tau compared to PS19 tau transgenic mice expressing Msut2. Conversely, Msut2 overexpression in 4RTauTg2652 tau transgenic mice increased pathological tau deposition and promoted the neuroinflammatory response to pathological tau. MSUT2 is a poly(A) RNA binding protein that antagonizes the canonical nuclear poly(A) binding protein PABPN1. In individuals with AD, MSUT2 abundance in postmortem brain tissue predicted an earlier age of disease onset. Postmortem AD brain tissue samples with normal amounts of MSUT2 showed elevated neuroinflammation associated with tau pathology. We observed co-depletion of MSUT2 and PABPN1 in postmortem brain samples from a subset of AD cases with higher tau burden and increased neuronal loss. This suggested that MSUT2 and PABPN1 may act together in a macromolecular complex bound to poly(A) RNA. Although MSUT2 and PABPN1 had opposing effects on both tau aggregation and poly(A) RNA tail length, we found that increased poly(A) tail length did not ameliorate tauopathy, implicating other functions of the MSUT2/PABPN1 complex in tau proteostasis. Our findings implicate poly(A) RNA binding proteins both as modulators of pathological tau toxicity in AD and as potential molecular targets for interventions to slow neurodegeneration in tauopathies.

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
LTLaura Garcia Toscano
Laura Garcia Toscano
JHJoshua Hincks
Joshua Hincks
PMPamela Mcmillan
Pamela Mcmillan
MBMisa Baum
Misa Baum
NLNicole Liachko
Nicole Liachko